COVID Vaccine Developer/Manufacturer Announcements

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]


Press Releases – No new digest announcements identified


Bharat Biotech
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias – [Website not responding at inquiry; receiving 403-Forbidden]


News – [Website not responding at inquiry]

Clover Biopharmaceuticals – China
News – No new digest announcements identified


Curevac [Bayer Ag – Germany]
News – No new digest announcements identified


Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

Home – No new digest announcements identified


Press Releases
Dec 03, 2021
United States
Janssen to Showcase Progress on Respiratory Syncytial Virus (RSV) Vaccine Candidate at ESWI 2021

Nov 29, 2021
United States
Johnson & Johnson to Evaluate Its COVID-19 Vaccine Against New Omicron COVID-19 Variant
Since the emergence of the COVID-19 pandemic, Johnson & Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as needed…


Press Releases
December 1, 2021
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
Agreement includes 29 million doses for delivery in 2022 and 31 million doses for delivery in 2023


Press Releases
Novavax Statement on Omicron Variant Response
Dec 2, 2021
Novavax is rapidly responding to the emergence of the latest potential threat of the SARS-CoV-2 Omicron (B.1.1.529) variant of concern (VoC). The company is executing a two-pronged variant strategy.
First, Novavax is evaluating its vaccine against the Omicron variant, as the company has done for previous variants including Alpha, Beta and Delta. Second, Novavax has initiated development of an Omicron-specific vaccine construct…


Recent Press Releases – No new digest announcements identified


Sanofi Pasteur
Press Releases
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
December 01 2021
Broad pipeline of innovative vaccines, with a total of 10 candidates planned to advance into the clinic by 2025, six of which will leverage the recently established mRNA Center of Excellence


Serum Institute of India
NEWS & ANNOUNCEMENTS – No new digest announcements identified


News – No new digest announcements identified


Press Releases
Instituto Butantan and SINOVAC will hold ‘CoronaVac® Symposium’ international event about efficacy and security of CoronaVac®


Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]



Press releases for media
02 December 2021
GSK welcomes Gavi decision to fund the roll out of malaria vaccines for children
Gavi to provide funding for procurement and introduction of malaria vaccines into child immunisation programmes in Gavi eligible countries.

02 December 2021
GSK and the University of Oxford launch new Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease
:: Major new collaboration aims to deepen understanding of complex diseases such as Alzheimer’s and Parkinson’s, and increase drug discovery and development success rates
:: New Institute to be based at Oxford’s Nuffield Department of Medicine

02 December 2021
Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant
:: Data to be confirmed by further in vitro pseudo-virus testing

30 November 2021
GSK appoints Phil Dormitzer M.D., Ph.D., as Global Head of Vaccines R&D
Phil Dormitzer M.D., Ph.D., will join the company as Global Head of Vaccines R&D on 3 December 2021


News releases
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
December 3, 2021

Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigational Oral Antiviral Molnupiravir for Treatment of Mild to Moderate COVID-19 in High Risk Adults
November 30, 2021


News – No new digest announcements identified


SK Biosciences
Press releases – No new digest announcements identified


Press Releases
December 3, 2021
Valneva Comments on COV-Boost Clinical Trial Data

December 2, 2021
Valneva Confirms Initiation of Rolling Review with EMA and Provides Updates on its COVID-19 Vaccine Program VLA2001

November 29, 2021
Valneva and IDT Biologika Announce Collaboration for Production of Inactivated COVID-19 Vaccine VLA2001